SCHEMBL5872172

SCHEMBL5872172

CCCOC(=O)C(Cc1cc[c]cc1)C(=O)OCCC

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.41
ALDH1A1 P00352 5/20 0.40
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
ESR1 P03372 1/20 0.38
CHRM1 P11229 1/20 0.38
TSHR P16473 1/20 0.38
SLC6A2 P23975 1/20 0.38
KDR P35968 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
LDHA P00338 1/20 0.38
PTPRB P23467 1/20 0.37
PPARG P37231 3/20 0.36
PPARD Q03181 2/20 0.36
PPARA Q07869 2/20 0.36
TP53 P04637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
NPY1R P25929 1/20 0.34
NPY2R P49146 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871668 0.90 TSHR (0.42) MMP8ALDH1A1LMNASMN1; SMN2ESR1
SCHEMBL5871820 0.89 TSHR (0.44) MMP8ALDH1A1LMNASMN1; SMN2TSHR
SCHEMBL5871978 0.88 ALDH1A1 (0.45) ALDH1A1LMNASMN1; SMN2ESR1TSHR
SCHEMBL5872055 0.86 MMP8 (0.54) MMP8ALDH1A1SMN1; SMN2TSHRTDP1
SCHEMBL14199944 0.83 MMP8 (0.58) MMP8ALDH1A1LMNASMN1; SMN2CHRM1
SCHEMBL5871840 0.81 PTPRB (0.54) MMP8ALDH1A1ESR1LDHAPTPRB
SCHEMBL19413780 0.80 LMNA (0.45) MMP8ALDH1A1LMNASMN1; SMN2ESR1
SCHEMBL19413788 0.75 MAPT (0.50) ALDH1A1LMNASMN1; SMN2TSHRTP53
SCHEMBL6027407 0.74 LDHA (0.40) MMP8LMNAESR1LDHAPTPRB
SCHEMBL16732085 0.73 TSHR (0.55) MMP8ALDH1A1LMNACHRM1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 MMP8 4083/4885ALDH1A1 272/4885LMNA 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.